Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 4/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.39 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.39 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.37 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL257319 | 0.83 | PTPN11 (0.48) | PTPN11PTPN1KDM4EGAAHSD17B10 | |
| SCHEMBL5654842 | 0.82 | ALDH1A1 (0.47) | PTPN11PTPN1KDM4EGAAHSD17B10 | |
| SCHEMBL14944883 | 0.80 | PTPN11 (0.55) | PTPN11PTPN1KDM4EGAAHSD17B10 | |
| SCHEMBL22900317 | 0.79 | PTPN11 (0.41) | PTPN11PTPN1KDM4EGAAHSD17B10 | |
| SCHEMBL12595077 | 0.78 | PTPN11 (0.48) | PTPN11PTPN1KDM4EGAAHSD17B10 | |
| SCHEMBL25107120 | 0.75 | LMNA (0.40) | PTPN11PTPN1KDM4EGAAHSD17B10 | |
| SCHEMBL5262949 | 0.75 | PTPN11 (0.48) | PTPN11PTPN1KDM4EGAAHSD17B10 | |
| SCHEMBL245270 | 0.75 | PTPN11 (0.48) | PTPN11PTPN1KDM4EGAAHSD17B10 | |
| SCHEMBL3275924 | 0.75 | PTPN11 (0.54) | PTPN11PTPN1KDM4EGAATXNRD1 | |
| SCHEMBL4682270 | 0.75 | PTPN11 (0.48) | PTPN11PTPN1KDM4EGAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230112086-A1 | PHOTO-CLEAVABLE PRIMER COMPOSITIONS AND METHODS OF USE | ORMCO CORPORATION | 2023-04-13 | — | — | US | disclosed |
| US-11453790-B2 | Photo-cleavable primer compositions and methods of use | ENVISTA (US) | 2022-09-27 | — | — | US | disclosed |
| US-20200347248-A1 | PHOTO-CLEAVABLE PRIMER COMPOSITIONS AND METHODS OF USE | ENVISTA (US) | 2020-11-05 | — | — | US | disclosed |
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100041618-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | ENANTA PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20080262208-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | WANG GUOQIANG | 2008-10-23 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
| WO-2007139856-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11453790-B2 | Photo-cleavable primer compositions and methods of use | SP1, GPER1, ESR1 | PTPN11 4409/4885CNR1 1675/4885CNR2 3083/4885 |
| US-20200347248-A1 | PHOTO-CLEAVABLE PRIMER COMPOSITIONS AND METHODS OF USE | SP1, GPER1, ESR1 | PTPN11 4409/4885CNR1 1675/4885CNR2 3083/4885 |
| US-20230112086-A1 | PHOTO-CLEAVABLE PRIMER COMPOSITIONS AND METHODS OF USE | SP1, GPER1, ESR1 | PTPN11 4409/4885CNR1 1675/4885CNR2 3083/4885 |
| US-20100041618-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | CYP2D6, CYP2B6, CYP1B1 | PTPN11 704/4885CNR1 2517/4885CNR2 2649/4885 |
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | PTPN11 3568/4885CNR1 423/4885CNR2 373/4885 |
| US-20080262208-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | CYP2D6, CYP2B6, CYP1B1 | PTPN11 704/4885CNR1 2517/4885CNR2 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.